Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development. Etigilimab is an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity. Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late line ovarian cancer.
종목 코드 MREO
회사 이름Mereo BioPharma Group PLC
상장일Jun 09, 2016
설립일2015
CEODr. Denise V. Scots-Knight, Ph.D.
직원 수36
유형Depository Receipt
회계 연도 종료Jun 09
주소One Cavendish Place
도시LONDON
증권 거래소NASDAQ Capital Market Consolidated
국가United Kingdom
우편 번호W1G0QF
전화443330237300
웹사이트https://www.mereobiopharma.com/
종목 코드 MREO
상장일Jun 09, 2016
설립일2015
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음